The industry trade group PhRMA has new clinical trial guidelines that take effect today, reports the Wall Street Journal Health Blog. The new rules discourage ghostwriting — "authors should identify individuals who provide writing or other assistance and disclose the funding source for this assistance" — and says that doctors who have a financial stake in a drug should not be involved in a clinical trial of that drug. The guidelines also say that drug companies should post summaries of clinical trial results. However, as the Health Blog says, there is a "big grain of salt" — all the guidelines are voluntary.
New Rules: Oct 1, 2009
Oct 01, 2009